In 2002, the Pediatric Eye Disease Investigator Group (PEDIG) compared penalization with atropine sulfate vs patching for treating moderate amblyopia.1 That initial article did not include data on stereoacuity and fusion in these 2 groups because many of the patients receiving atropine sulfate were still pharmacologically dilated at the outcome examination. Readers were promised “definitive long-term safety data on the completion of the 2-year follow-up.”1 Although I eagerly awaited that publication, I was unsatisfied and somewhat distressed when I read it.2 I believe the study did not provide the long-term safety data that I had anticipated.
Kushner BJ. Concern About the Pediatric Eye Disease Investigator Group 2-Year Follow-up Study. Arch Ophthalmol. 2005;123(11):1615-1616. doi:10.1001/archopht.123.11.1615-b